Niraparib

BNF:
Not listed
Status:
Red
Decision Date:
August 2018
 

Comments

RED1,2,3,8: NICE TA528 -  maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer.

RED1,2,3,8: NICE TA673- maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. NHSE commissioned (Decision date - March 2021)

RED1,2,3,8NICE TA784- maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer. (Decision date - May 2022)

NHSE commissioned

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app